Together, these results demonstrate that co-targeting LIFR and MEK pathways using EC359 and trametinib provides superior anti-tumor efficacy in both xenograft and PDX models, without inducing observable toxicity, supporting its potential as a promising therapeutic strategy. Here, LIFR is linked to neoplasm.